Sequenom, Inc. Announces Date Of First Quarter 2014 Financial Results And Conference Call
PR Newswire - Thu Apr 17, 6:00AM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the first quarter of 2014 after closing of the NASDAQ Global Market on Thursday, May 1, 2014.
Could A Nasdaq Correction Benefit These 8 Value Stocks?
at The Street - Wed Apr 16, 4:34PM CDT
a����James Dennin, Kapitall: Value investors pick up shares during market corrections. Could Nasdaq's performance benefit these 9 value stocks? Everyone's [...]
Global SNP Genotyping and Analysis Market Forecasts & Opportunities 2013-2019
M2 - Mon Apr 14, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bk2mlx/snp_genotyping) has announced the addition of the "Global SNP Genotyping and Analysis Market Forecasts & Opportunities 2013-2019" report to their offering. The global market is expected to reach USD 9,485.2 million by 2019, up from USD 2,385.2 million in 2012, growing at a CAGR of 21.8% The study elucidates the market dynamics, which are the drivers, restraints and opportunities that a market player will come across in this area. It gives a brief introduction to each topic as it covers the commercial aspects of the market and its technologies along with current trends. The report analyzes four major applications of SNP genotyping in Life Sciences and Healthcare industry which are Pharmaceutical/Pharmacogenomics, Diagnostics, Agricultural Biotechnology and Breeding and Animal Livestock. The market products are internally affected by power of substitution since there are around 8 to 10 different efficient techniques to carry out SNP genotyping such as TaqMan, SNPlex, Microarray, MALDI-TOF etc. With the completion of the Human Genome Project, over 2 million SNP's have been added to global databases which in turn have initiated a series of research and development projects to understand potential of developing diagnostic tests through rapid genotyping techniques. A considerable amount of revenue is spent on research to developing diagnostic products similar to companion diagnostics which would enable to give us a preview of how a genome would unfold as an individual grows older. There is a high intensity of research in food crops such as rice, wheat, oats, corn, maize and other grasses. SNP genotyping in agriculture gained acceptance long before other applications. The GeneChip Rice 44K array offered by Affymetrix is one of the most popular platforms for rice genotyping which identifies variants that impact yield. Fluidigm's SNPtype assays have been utilized by International Rice Research Institute which holds the world's largest ex-situ collection of rice germplasm and plays a very large role in maintaining this repository. Scope of the Report Technology - SNP GeneChips and Microarrays - Taqman Allelic Discrimination - SNP by Pyrosequencing - AB SNPlex - MassARRAY MALDI-TOF - Others Application - Pharmaceuticals and Pharmacogenomics - Diagnostic Research - Agricultural Biotechnology - Breeding and Animal Livestock Key Topics Covered: - Introduction - Executive Summary - Market Overview: Global SNP Genotyping & Analysis Market - Global SNP Genotyping & Analysis Market, by Technologies, 2011 - 2019 (USD Million) - Global SNP Genotyping and Analysis Market, by Applications, 2011 - 2019 (USD Million) - Global SNP Genotyping and Analysis Market, by Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Company Profiles - Affymetrix, Inc - Douglas Scientific LLC - Fluidigm - Illumina, Inc - Life Technologies Corporation - PREMIER Biosoft - Sequenom, Inc - ThermoFisher Scientific Visit http://www.researchandmarkets.com/research/bk...genotyping
Prenatal and New-born Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 27, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4qf5z/prenatal_and) has announced the addition of the "Prenatal and New-born Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Prenatal testing and diagnosis have enabled the detection of certain genetic abnormalities in as early as 8 to 10 weeks of gestation and also helps to determine the sex of the fetus. Prenatal and newborn genetic testing is referred to as the utilization of screening/diagnostic procedures for a fetus or a new born baby to detect chromosomal abnormalities such as Down syndrome, Patau syndrome and Edward syndrome. This report studies the global prenatal and newborn genetic testing market from two perspectives namely, types of technologies and the major geographic markets. The global prenatal and newborn genetic testing market by technology has been segmented as diagnostic technique and screening methods. Diagnostic technique is further classified as polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization (aCGH). Similarly, screening methods are further categorized as non-invasive prenatal tests and maternal serum screening. Key Topics Covered: Introduction Executive Summary Prenatal and Newborn Genetic Testing Market Overview Prenatal and Newborn Genetic Testing Market, by Technology Prenatal and Newborn Genetic Testing Market, by Geography Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Agilent Technologies, Inc. - Ariosa Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Sequenom, Inc. For more information visit http://www.researchandmarkets.com/research/r4...enatal_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom and Former CFO Resolve Litigation
PR Newswire - Fri Mar 21, 4:00PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced a resolution of litigation between the Company and Paul Hawran. Mr. Hawran served as the Company's Chief Financial Officer from April 2007 until September 2009. Mr. Hawran resigned in September 2009.
Sequenom (SQNM) Soars: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:51AM CDT
Sequenom Inc. was a big mover last session, as its shares rose over 6% on the day.
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
Sequenom Up 5.8%, Shares Break Through Resistance (SQNM)
Comtex SmarTrend(R) - Wed Mar 19, 11:40AM CDT
Sequenom (NASDAQ:SQNM) is one of today's best performing low-priced stocks, up 5.8% to $2.46 on 1.6x average daily volume. Thus far today, Sequenom has traded 2.8 million shares, vs. average volume of 1.8 million shares per day. The stock has outperformed the Dow (5.8% to the Dow's -0.0%) and outperformed the S&P 500 (5.8% to the S&P's -0.0%) during today's trading.
US Non-Invasive Prenatal Testing Market Outlook 2018 Provides Detailed Insight into the Current Scenario and Future Outlook
M2 - Tue Mar 18, 11:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s8n285/us_noninvasive) has announced the addition of the "US Non-Invasive Prenatal Testing Market Outlook 2018" report to their offering. The average age of women giving birth in United States has increased over the years. It's no longer unusual for women to have a first child at age 35 or even 40. This trend has been attributed to numerous factors such as recession and associated affordability issues, and women being more focused on their careers than before. However, increased age of the mother also increases the risk of her child developing chromosomal abnormalities. This risk has thus paved the way for NIPT tests which have emerged as the next big thing in the field of prenatal diagnostics. According to the report, US Non-Invasive Prenatal Testing Market Outlook 2018, the rise in high risk births has been contributing to the growth of the NIPT market which is anticipated to grow at a CAGR of over 20% for the next 5 years.This market's potential and the actual market have been deduced and it has been inferred that 2/3 rd of the total market remains untapped. Contribution of every NIPT player has also been provided in terms of current and future market shares. The demographic scenario of United States has been discussed with focus on the current and future number of births, with the demographics segregated by age and state. Although, the market has witnessed stupendous growth and new tests have gained acceptance rapidly, much of it still remains untapped due to various reasons. This has been discussed in the section dedicated to the potential market for 2013 and 2018. A thorough analysis has been done illustrating the views of regulatory authorities, players and consumers towards regulatory stringency and the direction of regulations in the future have also been covered. Companies Mentioned: - Ariosa Diagnostics - Natera - Sequenom - Verinata For more information visit http://www.researchandmarkets.com/research/s8...oninvasive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Non-Invasive Prenatal Testing (NIPT) Market 2013-2019: MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest and BambniTest
M2 - Tue Mar 18, 11:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f6m44q/noninvasive) has announced the addition of the "Non-Invasive Prenatal Testing (NIPT) Market 2013-2019: MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest and BambniTest" report to their offering. Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), and also for fetal sex determination. This report studies the current market scenario and future potential for non-invasive prenatal tests globally. The major NIPTs studied in this report are MaterniT21 PLUS, Harmony, Panorama, verifi, NIFTY, PrenaTest and BambniTest. These tests have been extensively analyzed on the basis of factors such as the technology used, testing cost, reimbursement coverage and geographical reach (availability across various countries). The market size and forecasts for each of these tests have been provided in terms of USD million for the period 2012 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for the market for each test for the forecast period 2013 to 2019. In this research study, the global market for NIPT has been geographically segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2012 to 2019 along with the CAGR for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in various countries of these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities along with the Porter's five force analysis and market attractiveness analysis. The report also includes a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global NIPT market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. Scope of the Report Test - MaterniT21 PLUS - verifi - Harmony - Panorama - NIFTY - PrenaTest - BambniTest Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Non-Invasive Prenatal Testing Market Overview Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 - 2019 (USD Million) Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2019 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Ariosa Diagnostics, Inc. - BGI Health - Berry Genomics Co., Ltd - LifeCodexx AG - Natera, Inc. - Sequenom, Inc. - Verinata Health, Inc. For more information visit http://www.researchandmarkets.com/research/f6...oninvasive
US Non-Invasive Prenatal Diagnostics - Market Insight - 2013 Report: Focusing on Players such as Sequenom, Verinata, Ariosa and Natera
M2 - Tue Mar 11, 7:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bkvmt4/us_noninvasive) has announced the addition of the "US Non-Invasive Prenatal Diagnostics - Market Insight" report to their offering. The US prenatal diagnostics market is one of the largest markets in the world for foetal monitoring, diagnostics, and predictive testing. It consists of a series of physician prescribed tests for monitoring maternal and foetal health. The current invasive technologies such as CVS and amniocentesis that are used to detect chromosomal abnormalities pose serious risks of miscarriages and are being replaced by the non-invasive prenatal diagnostics technologies. Although NIPD is a relatively nascent segment of the prenatal diagnostics, it presents a lucrative growth potential to industry participants. The segment is mainly supported by rising incidences of foetal health-related abnormalities and the urgent need for safe, accurate and early diagnosis. Products such as MaterniT21 Plus, Verifi, and Harmony prenatal tests are the current tests available in the market. Around 100,000 samples were likely tested by MaterniT21 plus test alone by the first quarter of 2013 since its launch. Further the report US Non-Invasive Prenatal Diagnostics - Market Insight, provides a transparent view on the present regulatory framework elaborating on the existing loopholes. A thorough analysis has been done illustrating the views of regulatory authorities, players and consumers towards the regulatory stringency, and the direction of regulations in the future have also been covered. Currently, the US NIPD sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These companies are effectively taking steps to promote their LDTs among the US population especially targeting physicians to recommend their products. In future, the launch of Natera's test is expected to impact the market significantly, thereby boosting the potential size and sample volume. Companies Mentioned: - Ariosa Diagnostics - Natera - Sequenom - Verinata For more information visit http://www.researchandmarkets.com/research/bk...oninvasive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of the UK Hepatitis Diagnostics Market: Hospitals, Blood Banks, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
M2 - Mon Mar 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjsvbf/2014_analysis_of) has announced the addition of the "2014 Analysis of the UK Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures" report to their offering. The report presents a detailed analysis of the Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: - Hospitals - Commercial/Private Labs - Blood Banks - Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Companies Mentioned: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics/Grifols - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/rj...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom Announces Changes In Company Leadership
PR Newswire - Wed Mar 05, 6:00PM CST
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that Harry F. Hixson, Jr., Ph.D., will retire as Chief Executive Officer (CEO), effective as of the Company's 2014 Annual Meeting on June 10, 2014. William J. Welch, the Company's current President and Chief Operating Officer, will assume the role of CEO, effective as of the Annual Meeting and immediately upon Dr. Hixson's retirement as CEO.
Sequenom, Inc. Announces Participation At The 26th Annual Roth Conference
PR Newswire - Mon Mar 03, 6:00AM CST
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the 26th Annual Roth Conference at the Ritz Carlton in Dana Point, CA on March 9-12, 2014.
Why Sequenom (SQNM) Closed Lower on Friday
at The Street - Fri Feb 28, 3:45PM CST
Sequenom (SQNM) closed lower on Friday after quarterly revenue came in below expectations.
Hot Stock: Sequenom, Shares Drop 9.1% (SQNM)
Comtex SmarTrend(R) - Fri Feb 28, 10:13AM CST
Sequenom (NASDAQ:SQNM) is one of today's worst performing low-priced stocks, down 9.1% to $2.34 on 1.0x average daily volume. Sequenom has traded 2.0 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.6%) and underperformed the S&P 500 (-9.1% to the S&P's 0.6%) during today's trading.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
Sequenom's Q4 Loss Narrows 42% on Higher Laboratory Revenue
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 4:14PM CST
Small-cap life science company Sequenom reported its fourth-quarter earnings results after the closing bell tonight, highlighting a push toward smaller losses and lower cash burn. For the quarter, Sequenom reported a 34% increase in revenue to...
Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2013
PR Newswire - Thu Feb 27, 3:10PM CST
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, today reported total revenues of $45.1 million for the fourth quarter and $162.4 million for the full year of 2013. Net loss was $18.9 million, or $0.16 per share, for the fourth quarter and $107.4 million, or $0.93 per share, for the full year.
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Wed Feb 26, 5:00AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.